432 related articles for article (PubMed ID: 21273732)
1. Regional distribution of drug-metabolizing enzyme activities in the liver and small intestine of cynomolgus monkeys.
Nakanishi Y; Matsushita A; Matsuno K; Iwasaki K; Utoh M; Nakamura C; Uno Y
Drug Metab Pharmacokinet; 2011 Jun; 26(3):288-94. PubMed ID: 21273732
[TBL] [Abstract][Full Text] [Related]
2. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
3. Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone.
Uehara S; Uno Y; Nakanishi K; Ishii S; Inoue T; Sasaki E; Yamazaki H
Drug Metab Dispos; 2017 May; 45(5):457-467. PubMed ID: 28196829
[TBL] [Abstract][Full Text] [Related]
4. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat.
Kobayashi K; Urashima K; Shimada N; Chiba K
Biochem Pharmacol; 2002 Mar; 63(5):889-96. PubMed ID: 11911841
[TBL] [Abstract][Full Text] [Related]
5. Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys.
Uehara S; Murayama N; Nakanishi Y; Zeldin DC; Yamazaki H; Uno Y
J Pharmacol Exp Ther; 2011 Nov; 339(2):654-61. PubMed ID: 21849623
[TBL] [Abstract][Full Text] [Related]
6. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
8. Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes.
Yoda N; Emoto C; Date S; Kondo S; Miyake M; Nakazato S; Umehara K; Kashiyama E
Xenobiotica; 2012 Aug; 42(8):719-30. PubMed ID: 22324396
[TBL] [Abstract][Full Text] [Related]
9. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
10. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey.
Sharer JE; Shipley LA; Vandenbranden MR; Binkley SN; Wrighton SA
Drug Metab Dispos; 1995 Nov; 23(11):1231-41. PubMed ID: 8591724
[TBL] [Abstract][Full Text] [Related]
11. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation.
Pearce R; Greenway D; Parkinson A
Arch Biochem Biophys; 1992 Oct; 298(1):211-25. PubMed ID: 1381906
[TBL] [Abstract][Full Text] [Related]
12. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
Bullock P; Pearce R; Draper A; Podval J; Bracken W; Veltman J; Thomas P; Parkinson A
Drug Metab Dispos; 1995 Jul; 23(7):736-48. PubMed ID: 7587963
[TBL] [Abstract][Full Text] [Related]
13. Characterization of monkey cytochrome P450, P450 CMLd, responsible for S-mephenytoin 4-hydroxylation in hepatic microsomes of cynomolgus monkeys.
Ohmori S; Chiba K; Nakasa H; Horie T; Kitada M
Arch Biochem Biophys; 1994 Jun; 311(2):395-401. PubMed ID: 8203903
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based inactivation of CYP2C11 by diclofenac.
Masubuchi Y; Ose A; Horie T
Drug Metab Dispos; 2001 Sep; 29(9):1190-5. PubMed ID: 11502726
[TBL] [Abstract][Full Text] [Related]
16. Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates.
Mankowski DC; Lawton MP; Ekins S
Xenobiotica; 2000 Aug; 30(8):745-54. PubMed ID: 11037108
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison.
Löfgren S; Hagbjörk AL; Ekman S; Fransson-Steen R; Terelius Y
Xenobiotica; 2004 Sep; 34(9):811-34. PubMed ID: 15742976
[TBL] [Abstract][Full Text] [Related]
18. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
20. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
